A Phase 4 interventional study of Dexlansoprazole 60 MG in GERD and Proton Pump Inhibitor, sponsored by American University of Beirut Medical Center. Completed at 1 site in Lebanon. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-15.
Sponsored by American University of Beirut Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing dexlansoprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Dexlansoprazole · Gastroesophageal Reflux.
Among the 27 studies testing dexlansoprazole in Gastroesophageal Reflux, this one is the 20th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 4, and was the 23rd registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 27 studies testing dexlansoprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Dexlansoprazole: first FDA approval 2009 (DEXILANT). What it is approved for, and how studies give it, is on its page →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 7 · Phase 4 6
First in 2005; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 104 across the 27 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 27 have an industry lead sponsor. The 10 most frequent:
American University of Beirut Medical Center is the lead sponsor of 158 studies on the registry; 24 are open to participants now.
American University of Beirut Medical Center has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing dexlansoprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Dexlansoprazole modified release (MR), the R-enantiomer of Lansoprazole, is an FDA approved drug (2009) for the management of erosive esophagitis and nonerosive reflux disease 1. Dexlansoprazole has a unique dual delayed-release delivery system designed to address unmet needs that may accompany traditional proton pump inhibitors, with two separate pH-depended release phases, the first in the proximal duodenum and the second in the more distal small intestine. This dual release system extends the plasma concentration and pharmacodynamics effects beyond those of single-release PPIs, allowing for dosing at any time of the day without regard to meals 1. A study conducted by Fass et al. has shown that the use of dexlansoprazole MR 30 mg in patients with symptomatic GERD is significantly more effective than placebo in improving nocturnal heartburn, reducing GERD-related sleep disturbances, and consequently improving work productivity, sleep quality and quality of life 2.
Because of its pharmacokinetic properties, Dexlansoprazole modified release (MR) may prove beneficial in optimizing the management of GERD and the associated burdens that often surface after the heavy evening and Suhur meals, such as increased nocturnal symptoms and poor sleep quality.
To investigate the efficacy and quality of life improvement of Dexlansoprazole 60mg taken once daily at Iftar time in patients with known symptomatic heartburn exacerbated in Ramadan and who are not on daily treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
Drug: Dexlansoprazole 60 MG
This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
Also known as: Dexilant 60 MG
Heartburn Relief
The mean number of days during Ramadan with complete relief of heartburn symptoms, including nocturnal symptoms.
Time frame: 1 month
Days with partial relief of heartburn symptoms
Days with partial relief of heartburn symptoms
Time frame: 1 month
Days with relief of nocturnal heartburn symptoms
Days with relief of nocturnal heartburn symptoms
Time frame: 1 month
Improvement in sleep qualit
The number of nocturnal sleeping hours will be assessed daily
Time frame: 1 month
Side effects/tolerability of Dexlansoprazole 30mg vs. Dexlansoprazole 60mg
"Side effects and tolerability" Questionnaire
Time frame: 1 month
Plan to share: No
Ran from Feb 2017 to primary completion in Jul 2017, 5 months.
Of 30 phase 4 interventional studies under Gastroesophageal Reflux, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexlansoprazole
American University of Beirut Medical Center →